A novel BCR-ABL mutation predicts resistance to tyrosine kinase inhibitor (TKI) therapy by a unique mechanism in patients (pts) with Philadelphia-Positive (Ph+) leukemia.

被引：0
|
作者：
Quintas-Cardama, Alfonso
Cortes, Jorge
Kantarjian, Hagop M.
Talpaz, Moshe
Wu, Ji
Meng, Feng
Donato, Nicholas
机构：
[1] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4773
引用
收藏
页码：276B / 276B
页数：1
相关论文
共 50 条
  • [1] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
    Hofmann, WK
    Jones, LC
    Lemp, NA
    de Vos, S
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    Koeffler, HP
    BLOOD, 2002, 99 (05) : 1860 - 1862
  • [2] Mutations at residues 315 and 317 in the ABL kinase domain are the main cause of resistance to dasatinib in Philadelphia-Positive (Ph+) leukemia patients (pts).
    Soverini, Simona
    Martinelli, Giovanni
    Colarossi, Sabrina
    Gnani, Alessandra
    Castagnetti, Fausto
    Rosti, Gianantonio
    Bosi, Costanza
    Paolini, Stefania
    Rondoni, Michela
    Piccaluga, Pier Paolo
    Palandri, Francesca
    Giannoulia, Panagiota
    Marzocchi, Giulia
    Luatti, Simona
    Abruzzese, Elisabetta
    Iacobucci, Ilaria
    Testoni, Nicoletta
    Baccarani, Michele
    BLOOD, 2006, 108 (11) : 251A - 251A
  • [3] Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation
    Egan, Daniel N.
    Beppu, Lan
    Radich, Jerald P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (01) : 184 - 189
  • [4] DYNAMICS OF BCR-ABL KINASE DOMAIN MUTATIONS IN PHILADELPHIA-POSITIVE LEUKEMIA PATIENTS AFTER SEQUENTIAL TREATMENT WITH MULTIPLE TYROSINE KINASE INHIBITORS
    Soverini, S.
    Gnani, A.
    Colarossi, S.
    Castagnetti, F.
    Palandri, F.
    Giannoulia, P.
    Paolini, S.
    Abruzzese, E.
    Merante, S.
    De Matteis, S.
    Gozzini, A.
    Ciccarese, F.
    Poerio, A.
    Amabile, M.
    Iacobucci, I.
    Rosti, G.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA, 2008, 93 : S68 - S68
  • [5] Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Soverini, Simona
    Colarossi, Sabrina
    Gnani, Alessandra
    Castagnetti, Fausto
    Rosti, Gianantonio
    Bosi, Costanza
    Paolini, Stefania
    Rondoni, Michela
    Piccaluga, Pier Paolo
    Palandri, Francesca
    Giannoulia, Panagiota
    Marzocchi, Giulia
    Luatti, Simona
    Testoni, Nicoletta
    Iacobucci, Ilaria
    Cilloni, Daniela
    Saglio, Giuseppe
    Baccarani, Michele
    Martinelli, Giovanni
    HAEMATOLOGICA, 2007, 92 (03) : 401 - 404
  • [6] Predicting resistance to dasatinib therapy for patients with Philadelphia-positive leukemia with prior tyrosine kinase inhibitor failure
    Kaplan, Jason B.
    Platanias, Leonidas C.
    Giles, Francis J.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 1922 - 1923
  • [7] Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy
    Lee, Hun Ju
    O'Brien, Susan
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Faderl, Stefan
    Koller, Charles
    Konopleva, Marina
    Verstovsek, Srdan
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Burger, Jan A.
    Thomas, Deborah A.
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 659 - 659
  • [8] Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) developing resistance to imatinib.
    Pfeifer, H
    Wassmann, B
    Pavlova, A
    Mueller, M
    Wunderle, L
    Brueck, P
    Oldenburg, J
    Hochhaus, A
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2005, 106 (11) : 46A - 47A
  • [9] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Pfeifer, Heike
    Wassmann, Barbara
    Pavlova, Anna
    Wunderle, Lydia
    Oldenburg, Johannes
    Binckebanck, Anja
    Lange, Thoralf
    Hochhaus, Andreas
    Wystub, Silvia
    Brueck, Patrick
    Hoelzer, Dieter
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (02) : 727 - 734
  • [10] Efficacy and new mutation of Philadelphia-positive leukemia patients with highly nilotinib-resistant BCR-ABL mutations during dasatinib therapy
    Jiang, Qian
    Qi, Ya-Zhen
    Lai, Yue-Yun
    Jiang, Bin
    Jiang, Hao
    Sh, Hong-Xia
    Huang, Xiao-Jun
    LEUKEMIA & LYMPHOMA, 2013, 54 : 23 - 24
12345